JP2015214582A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015214582A5 JP2015214582A5 JP2015160099A JP2015160099A JP2015214582A5 JP 2015214582 A5 JP2015214582 A5 JP 2015214582A5 JP 2015160099 A JP2015160099 A JP 2015160099A JP 2015160099 A JP2015160099 A JP 2015160099A JP 2015214582 A5 JP2015214582 A5 JP 2015214582A5
- Authority
- JP
- Japan
- Prior art keywords
- her2
- antibody
- treatment
- her2 antibody
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 4
- 230000000306 recurrent effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims 5
- 206010027476 Metastases Diseases 0.000 claims 2
- 229960000397 bevacizumab Drugs 0.000 claims 2
- 230000009401 metastasis Effects 0.000 claims 2
- 238000009097 single-agent therapy Methods 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 1
- 230000002159 abnormal effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06017330.9 | 2006-08-21 | ||
| EP06017330 | 2006-08-21 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013103182A Division JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015214582A JP2015214582A (ja) | 2015-12-03 |
| JP2015214582A5 true JP2015214582A5 (cg-RX-API-DMAC10.html) | 2017-08-31 |
Family
ID=37607207
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524943A Pending JP2010501498A (ja) | 2006-08-21 | 2007-08-17 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2013103182A Withdrawn JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2015160099A Ceased JP2015214582A (ja) | 2006-08-21 | 2015-08-14 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524943A Pending JP2010501498A (ja) | 2006-08-21 | 2007-08-17 | 抗ｖｅｇｆ抗体による腫瘍治療 |
| JP2013103182A Withdrawn JP2013163687A (ja) | 2006-08-21 | 2013-05-15 | 抗ｖｅｇｆ抗体による腫瘍治療 |
Country Status (28)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1282443T1 (sl) | 2000-05-19 | 2010-01-29 | Genentech Inc | Metoda detekcije gena za izboljšanje verjetnosti učinkovitega odziva na terapijo raka z antagonistom ErbB |
| KR20150043558A (ko) * | 2004-07-22 | 2015-04-22 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| RU2438705C2 (ru) | 2005-01-21 | 2012-01-10 | Дженентек, Инк. | Введение фиксированных доз her-антител |
| CA2596133C (en) | 2005-02-23 | 2016-11-15 | Genentech, Inc. | Extending time to disease progression or survival in cancer patients |
| PE20070207A1 (es) * | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| ES2392630T3 (es) * | 2006-08-21 | 2012-12-12 | F. Hoffmann-La Roche Ag | Terapia antitumoral con anticuerpos anti-VEGF |
| AU2008223069B2 (en) | 2007-03-02 | 2012-12-13 | F. Hoffmann-La Roche Ag | Predicting response to a HER dimerisation inhibitor based on low HER3 expression |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| JP6320753B2 (ja) | 2010-05-27 | 2018-05-09 | ゲンマブ エー／エス | Ｈｅｒ２に対するモノクローナル抗体 |
| WO2011147982A2 (en) | 2010-05-27 | 2011-12-01 | Genmab A/S | Monoclonal antibodies against her2 epitope |
| AU2011281700B2 (en) * | 2010-07-19 | 2017-02-09 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer |
| BR112013004012B1 (pt) * | 2010-08-20 | 2021-03-23 | Novartis Ag | Anticorpo monoclonal isolado ou fragmento de ligação ao antígeno do mesmo ao receptor her3, seu uso e composição farmacêutica |
| AU2012245116A1 (en) | 2011-04-20 | 2013-11-07 | Genmab A/S | Bispecific antibodies against HER2 and CD3 |
| CN104334189A (zh) | 2011-10-14 | 2015-02-04 | 霍夫曼-拉罗奇有限公司 | Her2二聚化抑制剂帕妥珠单抗的用途和包含her2二聚化抑制剂帕妥珠单抗的制品 |
| AU2012348600A1 (en) * | 2011-12-05 | 2014-05-22 | F. Hoffmann-La Roche Ag | Blood plasma biomarkers for bevacizumab combination therapies for treatment of breast cancer |
| WO2013148159A1 (en) * | 2012-03-30 | 2013-10-03 | Fibrogen Inc | Therapeutic methods for peritoneal carcinomatosis |
| CA2907776C (en) | 2013-04-16 | 2020-04-14 | Genentech, Inc. | Pertuzumab variants and evaluation thereof |
| AU2015249633B2 (en) | 2014-04-25 | 2020-10-15 | Genentech, Inc. | Methods of treating early breast cancer with Trastuzumab-MCC-DM1 and Pertuzumab |
| TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗－ｏｘ４０抗體及其用途 |
| DK3302551T3 (da) | 2015-05-30 | 2024-08-26 | Hoffmann La Roche | Fremgangsmåder til behandling af HER2-positiv tidligere ubehandlet metastatisk brystkræft |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| CN106729743B (zh) | 2015-11-23 | 2021-09-21 | 四川科伦博泰生物医药股份有限公司 | 抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用 |
| TW202140776A (zh) | 2016-04-26 | 2021-11-01 | 美商美國泰福生技股份有限公司 | 細胞培養基 |
| JP6914336B2 (ja) | 2016-12-28 | 2021-08-04 | ジェネンテック， インコーポレイテッド | 進行したｈｅｒ２発現がんの治療 |
| EP3868404A1 (en) | 2017-01-17 | 2021-08-25 | F. Hoffmann-La Roche AG | Subcutaneous her2 antibody formulations |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| CA3059241A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| WO2022005499A1 (en) | 2020-06-29 | 2022-01-06 | Genentech, Inc. | Pertuzumab plus trastuzumab fixed dose combination |
| WO2022051721A1 (en) * | 2020-09-04 | 2022-03-10 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Combination compositions and methods for treating cancer |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3040121B2 (ja) | 1988-01-12 | 2000-05-08 | ジェネンテク，インコーポレイテッド | 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法 |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DK1975181T3 (da) | 1992-10-28 | 2011-06-06 | Genentech Inc | Anvendelse af vaskulære endothelcelle-vækstfaktor-antagonister |
| CA2259222A1 (en) | 1996-06-27 | 1997-12-31 | Pfizer Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors |
| CN101412758A (zh) | 1996-10-18 | 2009-04-22 | 基因技术股份有限公司 | 抗ErbB2抗体 |
| US6884879B1 (en) * | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP3957765B2 (ja) | 1997-04-07 | 2007-08-15 | ジェネンテク・インコーポレイテッド | 抗ｖｅｇｆ抗体 |
| US20020032315A1 (en) | 1997-08-06 | 2002-03-14 | Manuel Baca | Anti-vegf antibodies |
| ATE501170T1 (de) | 1997-04-07 | 2011-03-15 | Genentech Inc | Verfahren zur herstellung humanisierter antikörper durch randomisierte mutagenese |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| JPH11236333A (ja) | 1997-12-30 | 1999-08-31 | Pfizer Prod Inc | 抗ガン剤として有用なイミダゾリン−４−オン誘導体 |
| CA2332331A1 (en) | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
| ES2237125T3 (es) | 1998-08-27 | 2005-07-16 | Pfizer Products Inc. | Derivados de quinolin-2-ona utiles como agentes anticancerigenos. |
| KR20010072991A (ko) | 1998-08-27 | 2001-07-31 | 실버스타인 아써 에이. | 항암제로서 유용한 알키닐-치환된 퀴놀린-2-온 유도체 |
| AU1728800A (en) | 1998-11-18 | 2000-06-05 | Genentech Inc. | Antibody variants with higher binding affinity compared to parent antibodies |
| EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
| WO2000035956A1 (fr) | 1998-12-16 | 2000-06-22 | Kyowa Hakko Kogyo Co., Ltd. | Anticorps monoclonal anti-vegf humain |
| SK11002001A3 (sk) | 1999-02-11 | 2002-05-09 | Pfizer Products Inc. | Heteroarylom substituované chinolin-2-ónové deriváty použiteľné ako protinádorové prostriedky |
| US6586447B1 (en) | 1999-04-01 | 2003-07-01 | Pfizer Inc | 3,3-disubstituted-oxindole derivatives useful as anticancer agents |
| SI1187632T1 (sl) | 1999-05-14 | 2009-04-30 | Genentech Inc | Zdravljenje z anti-ErbB2 protitelesi |
| PT1189634E (pt) | 1999-06-25 | 2007-06-06 | Genentech Inc | Tratamento de cancro da próstata com anticorpos anti-erbb2. |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| SI2283867T1 (sl) | 1999-06-25 | 2014-07-31 | Immunogen, Inc. | Metode zdravljenja z majtanzinoidom konjugiranim protitelesom anti-ErbB |
| UA75055C2 (uk) | 1999-11-30 | 2006-03-15 | Пфайзер Продактс Інк. | Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі |
| DK1106612T3 (da) | 1999-11-30 | 2004-05-17 | Pfizer Prod Inc | Quinolinderivater, der er nyttige til inhibering af farnesylproteintransferase |
| HN2000000266A (es) | 2000-01-21 | 2001-05-21 | Pfizer Prod Inc | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. |
| WO2003042402A2 (en) * | 2001-11-13 | 2003-05-22 | Dana-Farber Cancer Institute, Inc. | Agents that modulate immune cell activation and methods of use thereof |
| AU2003222252A1 (en) | 2002-03-12 | 2003-09-29 | The General Hospital Corporation | Use of signal transduction inhibitors and combination therapies for the prevention or treatment of cancer and angiogenesis related diseases |
| WO2003087131A2 (en) | 2002-04-10 | 2003-10-23 | Genentech, Inc | Anti-her2 antibody variants |
| WO2005000900A1 (en) | 2003-05-30 | 2005-01-06 | Genentech, Inc. | Treatment with anti-vegf antibodies |
| WO2005000090A2 (en) | 2003-05-30 | 2005-01-06 | Medi-Screw, Inc. | Medical implant systems |
| KR20060069825A (ko) | 2003-08-01 | 2006-06-22 | 제넨테크, 인크. | 제한된 다양성을 갖는 항체 ｃｄｒ 폴리펩티드 서열 |
| US20050106667A1 (en) * | 2003-08-01 | 2005-05-19 | Genentech, Inc | Binding polypeptides with restricted diversity sequences |
| DK1718677T3 (da) | 2003-12-19 | 2012-07-09 | Genentech Inc | Monovalente antistoffragmenter egnede som terapeutiske midler |
| JP2008511337A (ja) * | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| WO2006042173A2 (en) * | 2004-10-04 | 2006-04-20 | Genentech, Inc. | Modulators of hepatocyte growth factor activator |
| BRPI0611766A2 (pt) * | 2005-06-08 | 2011-12-20 | Dana Farber Cancer Institute | métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada |
| TW200812615A (en) * | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
| ES2392630T3 (es) * | 2006-08-21 | 2012-12-12 | F. Hoffmann-La Roche Ag | Terapia antitumoral con anticuerpos anti-VEGF |
| JP2013103182A (ja) * | 2011-11-15 | 2013-05-30 | Toray Ind Inc | スパイラル型流体分離素子およびその製造方法 |
-
2007
- 2007-08-17 ES ES07786693T patent/ES2392630T3/es active Active
- 2007-08-17 MY MYPI20090667 patent/MY150756A/en unknown
- 2007-08-17 SG SG2011060142A patent/SG174090A1/en unknown
- 2007-08-17 AR ARP070103667A patent/AR062419A1/es unknown
- 2007-08-17 ES ES11193793.4T patent/ES2546066T3/es active Active
- 2007-08-17 RU RU2009110102/15A patent/RU2528884C2/ru not_active IP Right Cessation
- 2007-08-17 PL PL07786693T patent/PL2056874T3/pl unknown
- 2007-08-17 NZ NZ574580A patent/NZ574580A/en not_active IP Right Cessation
- 2007-08-17 JP JP2009524943A patent/JP2010501498A/ja active Pending
- 2007-08-17 AU AU2007287794A patent/AU2007287794B2/en not_active Ceased
- 2007-08-17 DK DK07786693.7T patent/DK2056874T3/da active
- 2007-08-17 CL CL200702404A patent/CL2007002404A1/es unknown
- 2007-08-17 CN CN2007800308557A patent/CN101505792B/zh not_active Expired - Fee Related
- 2007-08-17 CA CA002660681A patent/CA2660681A1/en not_active Abandoned
- 2007-08-17 EP EP11193793.4A patent/EP2441472B1/en not_active Revoked
- 2007-08-17 EP EP07786693A patent/EP2056874B1/en not_active Revoked
- 2007-08-17 US US11/840,279 patent/US20080050385A1/en not_active Abandoned
- 2007-08-17 KR KR1020097003557A patent/KR101136763B1/ko not_active Expired - Fee Related
- 2007-08-17 SI SI200731075T patent/SI2056874T1/sl unknown
- 2007-08-17 MX MX2009001715A patent/MX2009001715A/es active IP Right Grant
- 2007-08-17 BR BRPI0715829-7A2A patent/BRPI0715829A2/pt not_active Application Discontinuation
- 2007-08-17 WO PCT/EP2007/007276 patent/WO2008022746A1/en not_active Ceased
- 2007-08-20 PE PE2007001129A patent/PE20080911A1/es not_active Application Discontinuation
- 2007-08-20 TW TW099141756A patent/TW201107346A/zh unknown
- 2007-08-20 TW TW096130765A patent/TW200825106A/zh unknown
-
2009
- 2009-01-29 CR CR10590A patent/CR10590A/es not_active Application Discontinuation
- 2009-01-29 NO NO20090450A patent/NO20090450L/no not_active Application Discontinuation
- 2009-01-29 IL IL196810A patent/IL196810A0/en unknown
- 2009-02-19 ZA ZA2009/01200A patent/ZA200901200B/en unknown
- 2009-02-19 MA MA31650A patent/MA30654B1/fr unknown
- 2009-02-24 CO CO09018558A patent/CO6150193A2/es unknown
-
2010
- 2010-05-20 US US12/784,309 patent/US20100285010A1/en not_active Abandoned
-
2011
- 2011-05-19 US US13/111,784 patent/US20110223159A1/en not_active Abandoned
-
2012
- 2012-08-14 US US13/585,095 patent/US20130183292A1/en not_active Abandoned
-
2013
- 2013-05-15 JP JP2013103182A patent/JP2013163687A/ja not_active Withdrawn
-
2015
- 2015-03-30 IL IL238045A patent/IL238045A0/en unknown
- 2015-05-13 US US14/711,671 patent/US20150239969A1/en not_active Abandoned
- 2015-08-14 JP JP2015160099A patent/JP2015214582A/ja not_active Ceased
-
2017
- 2017-10-23 US US15/791,285 patent/US20180251536A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015214582A5 (cg-RX-API-DMAC10.html) | ||
| RU2009110102A (ru) | Лечение опухолей с помощью антитела к vegf | |
| AR062840A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti receptor del factor de crecimiento epidermico (her2) | |
| MX2018015353A (es) | Usos terapeuticos de un inhibidor de c-raf. | |
| WO2018136412A3 (en) | Subcutaneous her2 antibody formulations | |
| MY208022A (en) | Anti-claudin 18.2 antibody and application thereof | |
| SG10201804945WA (en) | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof | |
| JP2014509659A5 (cg-RX-API-DMAC10.html) | ||
| EA033400B1 (ru) | Антитело против cd3 и его применение | |
| RU2017144185A (ru) | Терапевтические комбинации и способы лечения новообразований | |
| MY205774A (en) | Human il-4r binding antibody, antigen binding fragment thereof, and medical use thereof | |
| MY198928A (en) | B7-h3 antibody, antigen-binding fragment thereof and medical use thereof | |
| EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
| JP2019506403A5 (cg-RX-API-DMAC10.html) | ||
| MX2017012965A (es) | Anticuerpo anti-c-met y conjugado de farmaco citotoxico de anticuerpo anti-c-met y uso farmaceutico del mismo. | |
| JO3784B1 (ar) | الاستخدام المشترك للاجسمام المضادة pd-1 ومضادات m-csf في علاج السرطان | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2014512354A5 (cg-RX-API-DMAC10.html) | ||
| JP2016520082A5 (cg-RX-API-DMAC10.html) | ||
| MX392487B (es) | Métodos y composiciones para dosificación en terapia celular adoptiva. | |
| MY183712A (en) | Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases | |
| JP2016515124A5 (cg-RX-API-DMAC10.html) | ||
| MX2020010119A (es) | Anticuerpo anti-cd27, fragmento de union a antigeno del mismo y uso medico del mismo. | |
| MX2020002750A (es) | Anticuerpo il-6r y fragmento de union a antigeno y uso medico. | |
| RU2017120361A (ru) | Антитела к pdgf-b и способы их применения |